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We report the first case of an HCV-positive recipient who was transplanted with an HCV-
positive graft with portal-portal bridging fibrosis. Curbing HCV infection immediately after 
liver transplant with direct-acting antivirals, resulted in an excellent 9-month outcome. 
  



































































Persistent organ shortage in liver transplantation (LT) forces transplant centers to use 
extended criteria donors. In this setting, hepatitis C virus (HCV)-positive livers represent a 
precious resource, but their use has been so far restricted to those with fibrosis stage ≤2 
according to Ishak (i.e. absence of bridging fibrosis), pending studies on fibrosis 
progression in grafts at more advanced stage (1). The same indication accrued from our 
own experience(2). In 1998 we used a 45-year-old HCV-positive graft having bridging 
fibrosis (staging 3/6, Ishak) in an HCV-positive recipient, Model for End-stage Liver 
Disease (MELD) 19 at LT; cold ischemia time (CIT) was 689 minutes and the patient 
experienced delayed non-function (prolonged ascites with progressive cholestasis), 
requiring re-LT on day 75.  
However, the recent advent of direct-acting antivirals (DAA) has revolutionized HCV 
therapy (32) and changes in the outcome of HCV-positive grafts can be expected.            
On December 10th, 2015, the 2771th LT was performed in Turin, Italy. The donor was a 46-
year-old male, deceased of anoxic brain injury. He was HCV positive, genotype 3a, 
inexperienced to antiviral therapy. Abdomen ultrasound (US) showed normal liver and 
spleen echogenicity and size. Platelet count was 229x109/L, total bilirubin 0.7 mg/dL, INR 
1.1, AST/ALT 98/171 IU/L, gamma-glutamyltransferase (GGT) 297 IU/L, HCV-RNA 
1,210,101 IU/mL, hepatitis B virus (HBV) core antibody positive. On retrieval, the liver was 
soft despite a grainy capsule (Fig.1A); biopsy showed fibrous expansion of most portal 
areas with evidence of portal-portal bridging (grading 4/18, staging 3/6, Ishak) (Fig.1B-C). 
The recipient, who signed an informed consent, was a 60-year old male, affected by 
HBV/HCV-related cirrhosis (HCV genotype 1b, non-responder to peginterferon/ribavirin), 
portal hypertension (large esophageal varices, spleen diameter 20 cm) and multinodular 
hepatocellular carcinoma beyond San Francisco criteria, successfully downstaged to Milan 
criteria. At LT, his MELD score was 8, creatinine clearance 98 mL/min, HCV-RNA 150,656 


































































IU/mL; HBV-DNA undetectable without treatment. CIT was 373 minutes; end-to-end biliary 
anastomosis with T-tube was performed; post-reperfusion biopsy showed moderate 
ischemia-reperfusion injury. Immediate graft function was satisfactory, with no ascites and 
no evidence of early/delayed dysfunction. Post-LT course was complicated by pneumonia 
due to a multi-sensitive Klebsiella pneumoniae, and he was discharged on day 26. 
Immunosuppression included tacrolimus, mycophenolate mofetil and steroids, the last 
weaned within 6 months. He underwent anti-HBV prophylaxis with lamivudine and 
hepatitis B immunoglobulin. Anti-HCV therapy with daily sofosbuvir (400 mg), daclatasvir 
(60 mg) and ribavirin at escalating dose (from 400 to 1000 mg) was started on the day of 
transplant for 24 weeks (according to Italian guidelines), with good tolerance. After LT, 
HCV-RNA was 4,407 IU/mL (HCV genotype 3a) at week 1; <15 IU/mL at week 2 and 
persistently undetectable since week 3. He achieved a sustained virological response at 
week 12 after end of therapy (SVR12). Transaminases and total bilirubin were persistently 
normal from week 4 after LT; GGT and alkaline phosphatase normalized from week 8. 
Liver stiffness, evaluated by transient elastography was 10.5 kilopascal (kPa) at week 12 
of therapy and it fell to 8.5 kPa at SVR12.  
On May 2nd, 2016, a T-tube cholangiography showed a mild biliary anastomotic stricture, 
which was managed by endoscopic stenting for 1 month. 
At SVR12, Doppler-US showed regular liver perfusion and reduction in spleen size (16.5 
cm), whilst upper endoscopy confirmed disappearance of the esophageal varices; 
magnetic resonance cholangiopancreatography evidenced a patent biliary anastomosis 
with normal intrahepatic bile ducts (Fig.2A); liver biopsy showed persistent fibrous 
expansion of most portal areas with occasional portal-portal bridging (grading 3/18, staging 
3/6, Ishak; Fig.2B-C).  
In conclusion, recourse to well-tolerated, pangenotipicpan-genotypic DAAs immediately 
after LT, allowed to cure the donor’s chronic hepatitis C into the recipient, thus affording a 


































































favorable short-term outcome, at variance with our previous unsuccessful case occurring 
in the interferon-era. The present report is a proof-of-concept that curbing HCV infection 
very early after LT, in association with CIT minimization and careful recipient selection, 
may result in excellent survival of HCV-positive grafts with portal-portal bridging, pending 
long-term fibrosis evaluation. This observation should encourage transplant teams to a 
more extensive use of HCV-positive donors, hopefully within the scope of an internationally 
agreed multicenter protocol. 
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Figure 1. Macroscopic and microscopic features of HCV-positive donor liver on 
retrieval. (A) Macroscopic appearance of the liver on retrieval: despite a grainy Glisson 
capsule, the parenchymal texture was soft on palpation, and no signs of portal 
hypertension were visible and spleen size was normal. (B) Portal inflammation with 
lymphocytic aggregate (empty arrow) and periportal hepatitis (arrows); grading 4/18 
according to Ishak score (Sirius Red staining; x 200 magnification). (C) Portal fibrosis 
(empty arrow) with portal-portal bridging (arrows) (staging 3/6 according to Ishak score) 
and diffuse mild macrovesicular and microvesicular steatosis (Masson's Trichrome 
staining, which was performed as an urgent procedure using rapid technique; x 100 
magnification). 
 
Figure 2. Biliary imaging and histology at 9-month follow-up after transplantation 
and subsequent very early viral eradication. (A) Magnetic resonance 
cholangiopancreatography showing normal intrahepatic bile ducts, patent biliary 
anastomosis (arrow) and mild dilatation of the extrahepatic bile duct. (B) Mild portal 
inflammation (arrow), focal periportal hepatitis (arrowhead) and focal lobular inflammation 
(empty arrow); grading 3/18 according to Ishak score (hematoxylin–eosin staining; x 100 
magnification). (C) Portal fibrosis (arrow) and thin portal-portal bridging (empty arrow); 
staging 3/6 according to Ishak score (Sirius Red staining; x 100 magnification). 



































































Figure 1. Macroscopic and microscopic features of HCV-positive donor liver on retrieval. (A) Macroscopic 
appearance of the liver on retrieval: despite a grainy Glisson capsule, the parenchymal texture was soft on 
palpation, no signs of portal hypertension were visible and spleen size was normal. (B) Portal inflammation 
with lymphocytic aggregate (empty arrow) and periportal hepatitis (arrows); grading 4/18 according to 
Ishak score (Sirius Red staining; x 200 magnification). (C) Portal fibrosis (empty arrow) with portal-portal 
bridging (arrows) (staging 3/6 according to Ishak score) and diffuse mild macrovesicular and microvesicular 
steatosis (Masson's Trichrome staining, which was performed as an urgent procedure using rapid technique; 
x 100 magnification).  
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Figure 2. Biliary imaging and histology at 9-month follow-up after transplantation and subsequent very early 
viral eradication. (A) Magnetic resonance cholangiopancreatography showing normal intrahepatic bile ducts, 
patent biliary anastomosis (arrow) and mild dilatation of the extrahepatic bile duct. (B) Mild portal 
inflammation (arrow), focal periportal hepatitis (arrowhead) and focal lobular inflammation (empty arrow); 
grading 3/18 according to Ishak score (hematoxylin–eosin staining; x 100 magnification). (C) Portal fibrosis 
(arrow) and thin portal-portal bridging (empty arrow); staging 3/6 according to Ishak score (Sirius Red 
staining; x 100 magnification).  
 
238x68mm (300 x 300 DPI)  
 
 
Page 9 of 9
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
